===
EQS-News: Medios AG / Key word(s): Quarterly / Interim Statement/Quarter Results
Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance
2024-05-07 / 07:31 CET/CEST
The issuer is solely responsible for the content of this announcement.
Press release

Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance

. Revenue increases by 5.8% to EUR456.2 million in the first quarter
. Cash flow from operating activities increases to EUR43.4 million
. Closing of the Ceban acquisition planned for May 2024
. Guidance 2024 confirmed: Significant increase in revenue and margin expected

Berlin, May 7, 2024 - Medios AG ("Medios"), the leading provider of Specialty Pharma solutions in Germany, confirms its
guidance for the 2024 financial year after a solid first quarter. Revenue increased by 5.8% year-on-year to EUR456.2
million in the period from January to March 2024 (previous year: EUR431.2 million). At EUR15.1 million (previous year:
EUR15.0 million), EBITDA pre^1 reached the level of the same quarter of the previous year. As a result, the EBITDA pre^1
margin of 3.3% (previous year: 3.5%) was slightly lower than in the same period of the previous year. Cash flow from
operating activities improved significantly in the first quarter of 2024 to EUR43.4 million (previous year:
EUR-25.3 million).
Heterogeneous sales and earnings development in the operating segments
The Pharmaceutical Supply segment achieved an increase in revenue of 8.9% to EUR401.0 million in the first quarter of
2024 (previous year: EUR368.1 million). The segment's EBITDA pre^1 increased by 9.0% to EUR11.0 million (previous year:
EUR10.1 million).
The Patient-Specific Therapies segment generated revenue of EUR55.1 million in the first quarter of 2024 after EUR62.9
million in the previous year. Around EUR3.5 million of this decline was attributable to the sale of Kölsche Blister GmbH
in June 2023. In addition, regulatory price adjustments in some compounding areas still had a negative impact on the
earnings development. As a result, the segment's EBITDA pre^1 decreased by 9.4% to EUR5.9 million (previous year: EUR6.6
million).
Matthias Gaertner, Chief Executive Officer (CEO) of Medios AG: "In the first quarter of 2024, we once again achieved an
increase in revenue and significantly increased our cash flow - despite the focus on the acquisition of Ceban, which we
expect to successfully complete shortly. With an even larger Medios Group, which will also operate internationally for
the first time, we expect to continue our successful growth trajectory for the rest of the 2024 financial year."
In the first quarter of 2024, Medios announced the acquisition of Ceban Pharmaceuticals B.V. ("Ceban"). Ceban is the
Dutch market leader in pharmaceutical compounding services and is also active in Belgium and Spain. In 2023, Ceban
generated revenue of approximately EUR160 million and an adjusted EBITDA of approximately EUR29 million, which corresponds
to an adjusted EBITDA margin of around 18%. The acquisition represents an important step in Medios' growth strategy,
which aims to build the leading European Specialty Pharma platform.
Positive outlook
Medios confirms the guidance for the 2024 financial year first announced on March 18, 2024. The company expects revenue
of EUR1.9 billion to EUR2.1 billion and EBITDA pre^1 of EUR82 million to EUR91 million. This expectation is based on the
assumption that the acquisition of Ceban Pharmaceuticals B.V. will be completed shortly and fully consolidated from the
beginning of May 2024.
In the medium term, the market share in the area of patient-specific therapies in particular is to be further expanded,
thereby increasing the profitability of the entire Medios Group. Accordingly, Medios is aiming for consolidated revenue
of more than EUR2bn and an EBITDA pre^1 margin at least in the mid-single-digit range in the medium term.

Key figures (IFRS)

in EUR million                          Q1 2024     Q1 2023    ? in % 
Revenue                                 456.2       431.2       5.8 
Pharmaceutical Supply                 401.0       368.1       8.9 
Patient-Specific Therapies             55.1        62.9     -12.5 
Services                                0.1         0.2     -23.3 
EBITDA pre^1                             15.1        15.0       0,6 
Pharmaceutical Supply                  11.0        10.1       9.0 
Patient Specific Therapies              5.9         6.6      -9.4 
Services                               -1.9        -1.7       9.8 
Cashflow from operating activities       43.4       -25.3   <-100.0 

===
Important dates for Medios AG in the 2024 financial year

June 6 to 7: Warburg Highlights - Hamburg

August 13: Half-Year Financial Report 2024

August 14: Annual General Meeting 2024

September 25: Berenberg and Goldman Sachs 13th German Corporate

Conference - Munich

November 12: Quarterly statement as of September 30, 2024

Medios AG's quarterly statement as of March 31, 2024 is available for download on the Investor Relations website.

^1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as for performance-related payments for the acquisition of compounding volumes and, from 2024, for expenses for the introduction of an ERP system.

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

c.nickolaus@medios.ag

www.medios.ag

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.

-----------------------------------------------------------------------------------------------------------------------

2024-05-07 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

-----------------------------------------------------------------------------------------------------------------------

===

Language:     English 
Company:      Medios AG 

Heidestraße 9
10557 Berlin
Germany

Phone:        +49 30 232 566 - 800 
Fax:          +49 30 232 566 - 801 
E-mail:       ir@medios.ag 
Internet:     www.medios.ag 
ISIN:         DE000A1MMCC8 
WKN:          A1MMCC 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1896957

End of News EQS News Service
===
1896957 2024-05-07 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1896957&application_name=news

END) Dow Jones Newswires

May 07, 2024 01:31 ET (05:31 GMT)